English

Elos Medtech - Year-end Report, 1 January - 31 December, 2022

Report this content

October – December 2022

  • Net sales for the fourth quarter amounted to SEK 229.5 (184.2) million, an increase of 24.6 percent compared to the same quarter last year. Net sales in local currencies increased by 13.8 percent.
  • Operating profit amounted to SEK 17.6 (25.3) million, corresponding to an operating margin of 7.7 (13.7) percent.
  • Profit after net financial items amounted to SEK 1.4 (24.8) million. Net financial items were negatively affected by exchange rates of SEK -8.3 (1.2) million and totaled SEK -16.3 (-0.5) million.
  • Profit after tax amounted to SEK 0.4 (19.5) million.
  • Cash flow from operating activities was SEK 18.3 (33.4) million, and SEK -10.7 (5.5) million after investments.
  • Earnings per share amounted to SEK 0.06 (2.42).

January – December 2022

  • Net sales for the year amounted to SEK 888.5 (723.6) million, an increase of 22.8 percent compared to last year. Net sales in local currencies increased by 13.5 percent.
  • Operating profit amounted to SEK 122.4 (101.1) million, corresponding to an operating margin of 13.8 (14.0) percent. Operating profit in the previous year includes a charge of SEK 15.6 million costs in connection with the completion of the offer from the new majority shareholder.
  • Profit after net financial items amounted to SEK 99.1 (98.0) million. Net financial items were negatively affected by exchange rates of SEK -9.2 (4.2) million and totaled SEK -23.3 (-3.1) million.
  • Profit after tax amounted to SEK 75.1 (75.6) million.
  • Cash flow from operating activities was SEK 108.3 (105.0) million, and SEK -9.0 (19.6) million after investments.
  • Earnings per share amounted to SEK 9.30 (9.37).

Dividend

  • The Board of Directors proposes that no dividend be paid for the 2022 financial year and that retained earnings be carried forward.

For further information, please contact:
Stefano Alfonsi, President and CEO, +44 772 04 98 342 , e-mail: stefano.alfonsi@elosmedtech.com
Ewa Linsäter, Group CFO, +46 76 633 32 33, e-mail: ewa.linsater@elosmedtech.com

This disclosure contains information that Elos Medtech AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on February 23, 2023, at 08:00 (CET). 

For additional information about the Elos Medtech Group, visit www.elosmedtech.com

Tags:

Year-End Report Medical Devices Elos Medtech medical technology

Subscribe

Documents & Links